You are here
Convenience, Compliance and Overcoming Clinical Inertia for Diabetes Specialists
for Diabetes Specialists
This course reviews the practical aspects of basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and shows how fixed-dose combination therapies provide added convenience that may help overcome clinical inertia related to insulin initiation and intensification. Clinical data will be presented to demonstrate how the efficacy and safety of basal insulin–GLP-1 receptor agonist combination therapy surpasses that of the individual components. After completing the course, participants will be able to identify patients for whom treatment with basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and know how to best manage these patients. Sign up to the E-Alert to be updated on all new publications.
Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk